Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 13/20 | 0.43 |
| ▸ | TCF7L2 | Q9NQB0 | 13/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1203791 | 0.93 | ALDH1A1 (0.46) | ALDH1A1P4HTMMAPTCTNNB1TCF7L2 | |
| SCHEMBL1202844 | 0.93 | CTNNB1 (0.47) | ALDH1A1P4HTMMAPTCTNNB1TCF7L2 | |
| SCHEMBL1202030 | 0.91 | ALDH1A1 (0.44) | ALDH1A1P4HTMMAPTCTNNB1TCF7L2 | |
| SCHEMBL1203737 | 0.90 | CTNNB1 (0.46) | ALDH1A1CTNNB1TCF7L2 | |
| SCHEMBL1203789 | 0.84 | NPC1 (0.48) | ALDH1A1MAPTCTNNB1TCF7L2 | |
| SCHEMBL1202935 | 0.84 | P4HTM (0.47) | P4HTMMAPTTP53 | |
| SCHEMBL1203131 | 0.83 | FYN (0.53) | ALDH1A1P4HTMMAPTTP53CXCR1 | |
| SCHEMBL1204006 | 0.83 | CTNNB1 (0.41) | ALDH1A1MAPTCTNNB1TCF7L2NPSR1 | |
| SCHEMBL1203647 | 0.83 | FLT1 (0.41) | ALDH1A1MAPTTP53 | |
| SCHEMBL1203106 | 0.82 | NTRK1 (0.49) | MAPTCXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | ALDH1A1 2356/4885P4HTM 1284/4885MAPT 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.